SKB 518
Alternative Names: SKB-518Latest Information Update: 21 May 2026
At a glance
- Originator Sichuan Kelun-Biotech Biopharmaceutical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA polymerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cervical cancer; Endometrial cancer; Lung cancer; Ovarian cancer
- Phase I/II Solid tumours
Most Recent Events
- 08 Apr 2026 Phase-II clinical trials in Cervical cancer (Monotherapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT07448922)
- 08 Apr 2026 Phase-II clinical trials in Endometrial cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (Parenteral) (NCT07448922)
- 08 Apr 2026 Phase-II clinical trials in Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT07448922)